Suppr超能文献

体位性心动过速综合征和血管迷走性晕厥患儿的诊断和治疗中的生物标志物和血流动力学参数。

Biomarkers and Hemodynamic Parameters in the Diagnosis and Treatment of Children with Postural Tachycardia Syndrome and Vasovagal Syncope.

机构信息

School of Public Health, Xi'an Jiaotong University, Xi'an 710061, China.

Department of Maternal and Child Health, School of Public Health, Xi'an Jiaotong University, Xi'an 710061, China.

出版信息

Int J Environ Res Public Health. 2022 Jun 7;19(12):6974. doi: 10.3390/ijerph19126974.

Abstract

In children, vasovagal syncope and postural tachycardia syndrome constitute the major types of orthostatic intolerance. The clinical characteristics of postural tachycardia syndrome and vasovagal syncope are similar but their treatments differ. Therefore, their differential diagnosis is important to guide the correct treatment. Therapeutic methods vary in patients with the same diagnosis because of different pathomechanisms. Hence, in patients with vasovagal syncope or postural tachycardia syndrome, routine treatments have an unsatisfactory efficacy. However, biomarkers could increase the therapeutic efficacy significantly, allowing for an accurate and detailed assessment of patients and leading to improved therapeutic effects. In the present review, we aimed to summarize the current state of research into biomarkers for distinguishing the diagnosis of pediatric vasovagal syncope from that of postural tachycardia syndrome. We also discuss the biomarkers that predict treatment outcomes during personalized therapy for each subtype.

摘要

在儿童中,血管迷走神经性晕厥和体位性心动过速综合征构成了主要的直立不耐受类型。体位性心动过速综合征和血管迷走神经性晕厥的临床特征相似,但治疗方法不同。因此,鉴别诊断对于指导正确的治疗非常重要。由于不同的病理机制,相同诊断的患者的治疗方法也有所不同。因此,血管迷走神经性晕厥或体位性心动过速综合征患者的常规治疗效果并不理想。然而,生物标志物可以显著提高治疗效果,对患者进行准确、详细的评估,从而改善治疗效果。在本综述中,我们旨在总结目前用于区分儿童血管迷走神经性晕厥和体位性心动过速综合征诊断的生物标志物的研究现状。我们还讨论了预测个体化治疗每种亚型治疗结局的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3248/9222341/22f30ba613a5/ijerph-19-06974-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验